



**TRANSMITTAL FORM**

Total Number of Pages in This Submission 17

Application Number	10/522,954
Filing Date	January 31, 2005
First Named Inventor	Beverly L. Davidson
Art Unit	1635
Examiner Name	Unknown
Attorney Docket Number	17023.045US2

**ENCLOSURES (Check all that apply)**

<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment/Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input checked="" type="checkbox"/> Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Reply to Missing Parts/Incomplete Application <input type="checkbox"/> Reply to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation <input type="checkbox"/> Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) _____ <input type="checkbox"/> Landscape Table on CD	<input type="checkbox"/> After Allowance Communication to TC <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below): Form 1449 (14 pgs.); Communication Concerning Related Applications (1 pg.); return postcard
Remarks _____		

**SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT**

Firm Name	VIKSNINS HARRIS & PADYS PLLP		
Signature			
Printed name	Peter L. Malen		
Date	March 31, 2006	Reg. No.	44,894

**CERTIFICATE OF TRANSMISSION/MAILING**

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below:

Signature		Date	March 31, 2006
Typed or printed name	Peter L. Malen		

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /K.C./



S/N 10/522,954

PATENTIN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Beverly L. Davidson et al. Examiner: Unknown  
Serial No.: 10/522,954 Group Art Unit: 1635  
Filed: January 31, 2005 Docket: 17023.045US2  
Title: ALLELE-SPECIFIC SIRNA-MEDIATED GENE SILENCING

COMMUNICATION CONCERNING RELATED APPLICATIONS

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

Applicants would like to bring to the Examiner's attention the following related applications.

Applications that claim priority to the related application(s) may be filed, and Applicants respectfully request that the Examiner additionally review those applications prior to issuing a Notice of Allowance in the present application.

Application Number	Filing Date	Docket Number
10/212,322	08/05/02	17023.023US1
10/430,351	05/05/03	17023.026US2
11/047,429	01/31/05	17023.026US3
10/738,642	12/16/03	17023.034US1
11/343,366	01/31/06	17023.045US3
10/859,751	06/02/04	17023.047US1
11/048,627	01/31/05	17023.053US1

Respectfully submitted,  
Beverly L. Davidson et al.  
By their Representatives,  
Viksnins Harris & Padys PLLP  
P.O. Box 111098  
Saint Paul, MN 55111  
952 876-4094

Date March 30, 2006By 

Peter L. Malen  
Reg. No. 44,894

CERTIFICATE UNDER 37 CFR 1.8: I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Mail Stop Amendment, Commissioner for Patents; P.O. Box 1450, Alexandria, VA 22313-1450, on this 31 day of March, 2006.

Name Signature 

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /K.C./

S/N 10/522,954

**PATENT****IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicant: Beverly L. Davidson et al.      Examiner: Unknown  
 Serial No.: 10/522,954      Group Art Unit: 1635  
 Filed: January 31, 2005      Docket: 17023.045US2  
 Title: ALLELE-SPECIFIC SIRNA-MEDIATED GENE SILENCING

**INFORMATION DISCLOSURE STATEMENT**

Mail Stop Amendment  
 Commissioner for Patents  
 P.O. Box 1450  
 Alexandria, VA 22313-1450

Sir:

In compliance with 37 C.F.R. § 1.56, and in accordance with 37 C.F.R. §§ 1.97 *et. seq.*, the enclosed materials are brought to the attention of the Examiner for consideration in connection with the above-identified patent application. Applicants respectfully request that this Information Disclosure Statement be entered and the documents listed on the attached Form 1449 be considered by the Examiner and made of record. Pursuant to MPEP 609, Applicants request that a copy of the Form 1449, initialed as being considered by the Examiner, be returned to the Applicants with the next official communication.


Copies of the "Foreign Patent Documents" and "Other Documents" listed on the Form 1449 are not included as these documents were either submitted to, or cited by, the Office in application Serial No. 10/212,322, which application is relied upon for an earlier effective filing date.

Pursuant to 37 C.F.R. § 1.97, no fee or statement is required with the Information Disclosure Statement. However, the Commissioner is hereby authorized to charge any required fees to Deposit Account No. 503503 in order to have this Information Disclosure Statement considered. The Examiner is invited to contact the Applicants' Representative at the below-listed telephone number if there are any questions regarding this communication.

Respectfully submitted,  
 Beverly L. Davidson et al.  
 By their Representatives,  
 Viksnins Harris & Padys PLLP  
 P.O. Box 111098  
 St. Paul, MN 55111  
 952 876-4094

Date March 30, 2006

By

  
 Peter L. Malen  
 Reg. No. 44,894

**CERTIFICATE UNDER 37 CFR 1.8:** I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Mail Stop Amendment; Commissioner for Patents; P.O. Box 1450, Alexandria, VA 22313-1450, on this 31 day of March, 2006.

Name

Signature

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /K.C./

Substitute for form 1449A/PTO and/or 1449B/PTO  
**INFORMATION DISCLOSURE  
 STATEMENT BY APPLICANT**  
 Use as many sheets as necessary



Complete if Known

Application Number	10/522,954
Filing Date	January 31, 2005
First Named Inventor	Beverly L. Davidson
Group Art Unit	1635
Examiner Name	Unknown

Sheet 1 of 14

Attorney Docket No: 17023.045US2

**US PATENT DOCUMENTS**

Examiner Initials *	US Document Number	Publication Date	Name of Patentee/Applicant of Document
	4,683,202	July 28, 1987	Mullis
	4,873,192	October 10, 1989	Kunkel
	4,962,091	October 9, 1990	Eppstein et al.
	5,350,674	September 27, 1994	Boenisch et al.
	5,580,859	December 3, 1996	Felgner et al.
	5,585,362	December 17, 1996	Wilson et al.
	5,814,500	September 29, 1998	Dietz
	5,837,449	November 17, 1998	Monia et al.
	5,902,880	May 11, 1999	Thompson
	5,922,602	July 13, 1999	Kumagai et al.
	5,928,906	July 27, 1999	Koster et al.
	5,972,704	October 26, 1999	Draper et al.
	6,001,990	December 14, 1999	Wands et al.
	6,177,246	January 23, 2001	Monia et al.
	6,387,616	May 14, 2002	Ozelius et al.
	6,420,345	July 16, 2002	Patel et al.
	6,468,524	October 22, 2002	Chiorini et al.
	6,479,291	November 12, 2002	Kumagai et al.
	6,506,559	January 14, 2003	Fire et al.
	6,531,647	March 11, 2003	Baulcombe et al.
	6,573,099	June 3, 2003	Graham

EXAMINER

DATE CONSIDERED

\* Examiner: Initial if document considered, whether or not the citation is in conformance with MPEP 608. Draw line through citation if not considered. Indicate copy of this form with date being cited to Applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /K.C./

Substitute for form 1449/APTO and/or 1449B/APTO  
**INFORMATION DISCLOSURE  
 STATEMENT BY APPLICANT**  
 (Use as many sheets as necessary)

Complete if Known

<b>Application Number</b>	10/522,954
<b>Filing Date</b>	January 31, 2005
<b>First Named Inventor</b>	Beverly L. Davidson
<b>Group Art Unit</b>	1635
<b>Examiner Name</b>	Unknown

Sheet 2 of 14

Attorney Docket No: 17023.045US2

6,794,414	September 21, 2004	Steinman
6,852,535	February 8, 2005	Thompson
2002/0086356	July 4, 2002	Tuschl et al.
2002/0132788	September 19, 2002	Lewis et al.
2002/0173478	November 21, 2002	Gewirtz
2003/0051263	March 13, 2003	Fire et al.
2003/0055020	March 20, 2003	Fire et al.
2003/0056235	March 20, 2003	Fire et al.
2003/0108923	June 12, 2003	Tuschl et al.
2004/0023390	February 5, 2004	Davidson et al.
2004/0192629	September 30, 2004	Xu et al.
2004/0241854	December 2, 2004	Davidson et al.
2005/0042646	February 24, 2005	Davidson et al.
2005/0106731	May 19, 2005	Davidson et al.
2005/0255086	November 17, 2005	Davidson et al.
2006/0009408	January 12, 2006	Davidson et al.

**FOREIGN PATENT DOCUMENTS**

Examiner Initials*	Foreign Document Number (include country code)	Publication Date	Translation (Abstract Only or Full Translation, if applicable)
	WO 90/14090	November 29, 1990	
	WO 94/01550	January 20, 1994	
	WO 94/07529	April 04, 1994	
	WO 99/32619	July 01, 1999	

EXAMINER

DATE CONSIDERED

\* Examiner: Initial if document considered, whether or not the citation is in accordance with MPEP 2139. If not, then the document is not considered for prior art purposes.  
 Substitute Information Disclosure Statement Form (PTO-1449)

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /K.C./

Substitute for form 1449A/PTO and/or 1449B/PTO  
**INFORMATION DISCLOSURE  
 STATEMENT BY APPLICANT**  
 (Use as many sheets as necessary)

Complete if Known

<b>Application Number</b>	10/522,954
<b>Filing Date</b>	January 31, 2005
<b>First Named Inventor</b>	Beverly L. Davidson
<b>Group Art Unit</b>	1635
<b>Examiner Name</b>	Unknown

Sheet 3 of 14

Attorney Docket No: 17023.045US2

**FOREIGN PATENT DOCUMENTS**

Examiner Initials*	Foreign Document Number (include country code)	Publication Date	Translation (Abstract Only or Full Translation, if applicable)
	WO 99/49029	September 30, 1999	
	WO 00/44895	August 03, 2000	Abstract only
	WO 01/29058	April 26, 2001	
	WO 01/70949	September 27, 2001	
	WO 01/75164	October 11, 2001	
	WO 02/44321	June 06, 2002	
	WO 02/55692	July 18, 2002	Abstract only
	WO 02/55693	July 18, 2002	Abstract only
	WO 03/06477	January 23, 2003	
	WO 03/08573	January 30, 2003	
	WO 03/10180	February 06, 2003	
	WO 03/22052	March 20, 2003	
	WO 03/23015	March 20, 2003	
	WO 03/080807	October 02, 2003	
	WO 04/013280	February 12, 2004	
	WO 04/047872	June 10, 2004	
	WO 04/058940	July 15, 2004	
	DE 10100586	April 11, 2002	Abstract only
	DE 10100588	July 18, 2002	Abstract only
	EP 1 144 623	October 17, 2001	
	EP 1 214 945	June 19, 2002	Abstract only

EXAMINER

DATE CONSIDERED

\* Examiner: Initial if document considered, whether or not the citation is in conformance with MPEP 609. Draw line through column if not considered. Include copy of this form with each communication to Applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /K.C./

Substitute for form 1449/APTO and/or 1449B/PTO  
**INFORMATION DISCLOSURE  
 STATEMENT BY APPLICANT**  
 (Use as many sheets as necessary)

Complete if Known

<b>Application Number</b>	10/522.954
<b>Filing Date</b>	January 31, 2005
<b>First Named Inventor</b>	Beverly L. Davidson
<b>Group Art Unit</b>	1635
<b>Examiner Name</b>	Unknown

Sheet 4 of 14

Attorney Docket No: 17023.045US2

**OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Include last name of the first author (in CAPITAL letters), Title of the Source (book, magazine, journal, serial, symposium, catalog, etc.), Volume-Number, page(s) and (date).
	Abdallah et al., <u>Biology of the Cell</u> , 1995, 85(1):1-7
	Abdelgany et al., <u>Hum. Mol. Genet.</u> , 2003, 12:2637-2644
	Adelman et al., <u>DNA</u> , 1983, 2:183
	Agrawal, <u>TIBTech</u> , 1996, 14:376-387
	Alisky et al., <u>Hum Gen Ther.</u> , 2000, 11:2315
	Alisky et al., <u>NeuroReport</u> , 2000, 11:2669
	Alisky et al., <u>Am J Pharmacogenomics</u> , 4(1):45-51 (2004).
	Altschul et al., <u>JMB</u> , 1990, 215:403
	Altschul et al., <u>Nucleic Acids Res.</u> 1997, 25:3389
	Ambrose et al., <u>Somat Cell Mol Genet.</u> , 1994, 20:27-38
	Ancellin et al., <u>The Journal of Biological Chemistry</u> , 2002, 277:6667-6675
	Anderson et al., <u>Gene Ther.</u> , 2000, 7(12):1034-1038
	Anderson, "Human Gene Therapy," <u>Nature</u> , 1998, 392:25-30
	Andreason and Evans, <u>Biotechniques</u> , 1988, 6:650
	Augood et al., <u>Ann. Neurol.</u> , 1999, 46:761-769
	Augood et al., <u>Neurology</u> , 2002, 59:445-448
	Bass, "The Short Answer," <u>Nature</u> , 2001, 411:428-429
	Bates et al., <u>Curr Opin Neurol.</u> , 2003, 16:465-470
	Batzner et al., <u>Nucl. Acids Res.</u> , 1991, 19:508
	Baulcombe, <u>Plant Mol. Biol.</u> , 1996, 32:79-88

EXAMINER

DATE CONSIDERED

Substitute Information Disclosure Statement Form (PTO-1449)  
 \* Examiner: Initial if document considered, whether or not the citation is in conformance with MPEP § 608. Draw line through citation if not considered. Include copy of this form with final communication to Applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. //K.C./

Substitute for form 1449A/PTO and/or 1449B/PTO  
**INFORMATION DISCLOSURE  
 STATEMENT BY APPLICANT**  
 (Use as many sheets as necessary)

Complete if Known

<b>Application Number</b>	10/522,954
<b>Filing Date</b>	January 31, 2005
<b>First Named Inventor</b>	Beverly L. Davidson
<b>Group Art Unit</b>	1635
<b>Examiner Name</b>	Unknown

Sheet 5 of 14

Attorney Docket No: 17023.045US2

**OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS**

**Examiner Initials\*** Include last name of the first author (in CAPITAL letters), Title of the Source (book, magazine, journal, serial, symposium, catalog, etc.), Volume-Number, page(s) and (date).

Behr et al., PNAS, 1989, 86:6982

Bernstein et al., Nature, 2001, 409:363-366

Bertrand et al., RNA, 1997 3(1):75-88.

Bledsoe et al., NatBiot, 2000, 18:964

Boado et al., J Pharmacol Exp Ther, 2000, 295(1):239-243.

Branch, TIBS, 1998, 23:45-50

Brantl, Biochimica et Biophysica Acta, 2002, 1575:15-25

Brash et al., Molec. Cell. Biol., 1987, 7:2031

Breakefield et al., Neuron, 2001, 31:9-12

Bridge et al., Nat Genet., 2003, 34:263-264

Brooks et al., PNAS, 2002, 99:6216-6221

Brummelkamp et al., Science, 2002, 296(5567):550-553.

Brummelkamp et al., Cancer Cell, 2002, 2:243-247

Burright et al., Cell, 1995, 82:937-948

Capecchi, Cell, 1980, 22:479

Caplen et al., PNAS, 2001, 98:9742-9747

Caplen et al., Hum. Mol. Genet., 2002, 11(2):175-184

Carter et al., J Neurosci., 1999, 19(8):3248-3257

Cemal et al., Hum. Mol. Genet., 2002, 11(9):1075-1094

Chai et al., Hum. Mol. Genet., 1999, 8:673-682

Chai et al., J. Neurosci., 1999, 19:10338-10347

EXAMINER

DATE CONSIDERED

Substitute Information Disclosure Statement Form (PTO 1449)

\* Examiner: Initial document considered, whether or not the document is a prior art document, is indicated by the "X" in the "Considered" column. If the document is not a prior art document, the "X" should be in the "Not Considered" column.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. //K.C./

Substitute for form 1449/APTO and/or 1449B/APTO  
**INFORMATION DISCLOSURE  
 STATEMENT BY APPLICANT**  
 (Use as many sheets as necessary)

Complete if Known

<b>Application Number</b>	10/522,954
<b>Filing Date</b>	January 31, 2005
<b>First Named Inventor</b>	Beverly L. Davidson
<b>Group Art Unit</b>	1635
<b>Examiner Name</b>	Unknown

Sheet 6 of 14

**Attorney Docket No:** 17023.045US2

**OTHER DOCUMENTS – NON PATENT LITERATURE DOCUMENTS**

**Examiner Initials\*** Include last name of the first author (in CAPITAL letters), **Title of the Source** (book, magazine, journal, serial, symposium, catalog, etc.), **Volume-Number**, page(s) and (date).

Chan et al., Hum Mol Genet., 2000, 9(19):2811-2820

Chiu and Rana, Mol. Cell., 2002, 10(3):549-561

Check, Nature, 2002, 417:779.

Check, Nature, 2004, 432, 136

Chen et al., Cell, 2003, 113(4):457-468

Clemens et al., PNAS, 2000, 97:6499-6503

Cogoni et al., Antonie Van Leeuwenhoek, 1994, 65:205-209

Corpet et al., Nucl. Acids Res., 1988, 16:10881

Cortez et al., Science, 2001, 294:1713-1716

Couzin, Science, 2004, 306, 1124-1125

Crea et al., PNAS, 1978, 75:5765

Cullen, Nat. Immunol., 2002, 3:597-599

Davidson et al., Nat Rev., 2003, 4(5):353-364

Davidson et al., The Lancet Neurol., 2004, 3:145-149

Davidson et al., PNAS, 2000, 97:3428-3432

Davidson et al., Meth Enzymol, 392:145-173, (2005).

Deng et al., J. Org. Chem., 1999, 64:202-208

Dillin, PNAS, 2003, 100:6289-6291

Ding et al., Aging Cell., 2003, 2:209-217

Doench et al., Genes Dev., 2003, 17(4):438-442

Doheny et al., Neurology, 2002, 59:1244-1246

**EXAMINER**

**DATE CONSIDERED**

\* Examiner: Initial if document considered, whether or not the citation is in accordance with MPEP 609. Citations listed through checking if not considered, include name of the form with new information to be added.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /K.C./

Substitute for form 1449A/PTO and/or 1449B/PTO  
**INFORMATION DISCLOSURE  
 STATEMENT BY APPLICANT**  
 (Use as many sheets as necessary)

Complete if Known

<b>Application Number</b>	10/522,954
<b>Filing Date</b>	January 31, 2005
<b>First Named Inventor</b>	Beverly L. Davidson
<b>Group Art Unit</b>	1635
<b>Examiner Name</b>	Unknown

Sheet 7 of 14

Attorney Docket No: 17023.045US2

**OTHER DOCUMENTS – NON PATENT LITERATURE DOCUMENTS**

**Examiner Initials\*** Include last name of the first author (in CAPITAL letters), **Title of the Source** (book, magazine, journal, serial, symposium, catalog, etc.), **Volume-Number**, page(s) and (date).

Donze et al., Nucleic Acids Research, 2002, 30(10):1-4

Elbashir et al., Nature, 2001, 411:494-498

Elbashir et al., Genes and Development, 2001, 15:188-200

Elbashir et al., EMBO J., 2001, 20(23):6877-6888

Emamian et al., Neuron, 2003, 38:375-87

Fahn et al., Adv. Neurol., 1998, 78: 1-10

Felgner et al., PNAS, 1987, 84:7413

Feng et al., Virology, 2000 25:276(2):271-278.

Fernandez-Funez et al., Nature, 2000, 408:101-106

Fire et al., Nature, 1998, 391:806-811

Garrus et al., Cell, 2001, 107:55-65

Gaspar et al., Am. J. Hum. Genet., 2001, 68(2):523-528

Gitlin et al., Nature, 2002, 418:430-434

Goeddel et al., Nucleic Acids Res., 1980, 8:4057

Gonzalez-Alegre et al., Ann Neurol., 2003, 53:781-787

Gonzalez-Alegre et al., J Neurosci., 2005; 25(45):10502-9.

Goodchild et al., Mov. Disord., 2002, 17(5):958, Abstract

Grishok et al., Science, 2000, 287:2494-2497

Hamilton and Baulcombe, Science, 1999, 286:950-952

Hammond et al., Nat Rev Genet, 2001;2(2):110-119.

Hammond et al., Nature, 2000, 404:293-296

EXAMINER

DATE CONSIDERED

\* Examiner: Initial if document considered, whether or not the citation is in conformance with MPEP 609. Draw line through citation if not considered. Include copy of this form with next communication to the Applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /K.C./

Substitute for form 1449A/PTO and/or 1449B/PTO  
**INFORMATION DISCLOSURE  
 STATEMENT BY APPLICANT**  
 (Use as many sheets as necessary)

Complete if Known

<b>Application Number</b>	10/522,954
<b>Filing Date</b>	January 31, 2005
<b>First Named Inventor</b>	Beverly L. Davidson
<b>Group Art Unit</b>	1635
<b>Examiner Name</b>	Unknown

Sheet 8 of 14

**Attorney Docket No:** 17023.045US2

**OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS**

**Examiner Initials\*** Include last name of the first author (in CAPITAL letters), Title of the Source (book, magazine, journal, serial, symposium, catalog, etc.), Volume-Number, page(s) and (date).

Hannon, Nature, 2002, 418:244-251

Haque et al., Exp Neurol, 1997; 144; 139-46.

Harborth et al., Journal of Cell Science, 2001, 114:4557-4565

Hardy et al., Science, 2002, 297(5580):353-356

Harper et al., Meth Mol Biol, 309:219-236 (2005).

Harper et al., PNAS, 102(16):5820-5825, (2005).

Hasholt et al., J Gene Med, 2003;5(6):528-38

Hewett et al., Hum. Mol. Gen., 2000, 9:1403-1413

Higgins et al., CABIOS, 1989, 5:151

Higgins et al., Gene, 1988, 73:237

Hilberg et al., PNAS, 1987, 84:5232

Holland et al., PNAS, 1987, 84:8662

Hornykiewicz et al., N. Engl. J. Med., 1986, 315:347-353

Houlden et al., Neurology, 2001, 56(12):1702-1706

Huang et al., CABIOS, 1992, 8:155

Hutton et al., Nature, 1998, 393:702-705

Jacque et al., Nature, 2002, 418(6896):435-438

Johnston, Nature, 1990, 346:776

Kao et al., J. Biol. Chem., 2004, 279:1942-1949

Karlin and Altschul, PNAS, 1990, 87:2264

Karlin and Altschul, PNAS, 1993, 90:5873

**EXAMINER**

**DATE CONSIDERED**

\* Examiner: Initial if document considered, whether or not the citation is in accordance with MPEP 2101. From the date through which a patent is granted, the date of publication of the form was determined. (2101.01)

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. //K.C./

Substitute for form 1449A/PTO and/or 1449B/PTO  
**INFORMATION DISCLOSURE  
 STATEMENT BY APPLICANT**  
 (Use as many sheets as necessary)

Complete if Known

<b>Application Number</b>	10/522,954
<b>Filing Date</b>	January 31, 2005
<b>First Named Inventor</b>	Beverly L. Davidson
<b>Group Art Unit</b>	1635
<b>Examiner Name</b>	Unknown

Sheet 9 of 14

Attorney Docket No: 17023.045US2

**OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS**

**Examiner Initials\*** Include last name of the first author (in CAPITAL letters), Title of the Source (book, magazine, journal, serial, symposium, catalog, etc.), Volume Number, page(s) and (date).

Kato et al., J Biol Chem., 2001, 76(24):21809-21820

Kawasaki et al., Nucleic Acids Res., 2003, 31(2):700-707

Kennerdell et al., Cell:95, 1017-1026 (1998).

Kennerdell et al., Nat Biotechnol. 2000;18(8):896-898.

Ketting et al., Nature, 2000, 404:296-298

Khvorova et al., 2003, Cell, 115:505

Kisielow et al., Biochem. J., 2002, 363:1-5

Kitabwalla and Ruprecht, N. Engl. J. Med., 2002, 347:1364-1367

Klein et al., Ann. Neurol., 2002, 52:675-679

Klein et al., Curr. Opin. Neurol., 2002, 4:491-497

Kunath et al., Nat Biotechnol. 2003, 21:559-561

Konakova et al., Arch. Neurol., 2001, 58:921-927

Koseki et al., J. Virol., 1999, 73:1868-1877

Krichevsky and Kosik, PNAS, 2002, 99(18):11926-11929

Kunkel et al., Meth. Enzymol., 1987, 154:367

Kunkel, PNAS, 1985, 82:488

Kustedjo et al., J. Biol. Chem., 2000, 275:27933-27939

Laccone et al., Hum. Mutat., 1999, 13(6):497-502

Lai et al., PNAS, 1989, 86:10006

Larrick and Burck, "Gene Therapy," Application of Molecular Biology, 1999, Elsevier Science Publishing Co., Inc., New York, p. 71-104

EXAMINER

DATE CONSIDERED

\* Examiner: Initial if document considered, whether or not the citation is in compliance with MPEP 608. Only list through Order 1 not considered. Include only if this form with oral communication to Applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /K.C./

Substitute for form 1449A/PTO and/or 1449B/PTO  
**INFORMATION DISCLOSURE  
 STATEMENT BY APPLICANT**  
 (Use as many sheets as necessary)

Complete if Known

<b>Application Number</b>	10/522,954
<b>Filing Date</b>	January 31, 2005
<b>First Named Inventor</b>	Beverly L. Davidson
<b>Group Art Unit</b>	1635
<b>Examiner Name</b>	Unknown

Sheet 10 of 14

Attorney Docket No: 17023.045US2

**OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS**

**Examiner  
Initials\***

Include last name of the first author (in CAPITAL letters), **Title of the Source** (book, magazine, journal, serial, symposium, catalog, etc.), **Volume-Number**, page(s) and (date).

Lawn et al., Nucleic Acids Res., 1981, 9:6103

Lee et al., Nature Biotechnology, 2002, 19:500-505

Lee et al., Annu Rev Neurosci., 2001, 24:1121-1159

Lee et al., Cell, 2004, 117:69-81

Leger et al., J. Cell. Sci., 1994, 107:3403-3412

Leung et al., Neurogenetics, 2001, 3:133-143

Lewis et al., Science, 2001, 293(5534):1487-1491

Lin et al., Hum. Mol. Genet., 2001, 10(2):137-144

Loeffler et al., J. Neurochem., 1990, 54:1812

Lotery et al., Hum Gene Ther., 2002, 13:689-696

Manche et al., Mol. Cell Biol., 1992, 12:5238

Margolis and Ross, Trends Mol. Med., 2001, 7:479-482

Martinez et al., Cell, 2002, 110(5):563-574

Martinez et al., PNAS, 2002, 99:14849-14854

McCaffrey et al., Nature, 2002, 418(6893):38-39

McManus et al., Nature Reviews Genetics, 2002, 3(10):737-747

Meinkoth and Wahl, Anal. Biochem., 1984, 138:267

Mercola et al., Cancer Gene Therapy, 1995, 2:47-59

Miller et al., PNAS, 2003, 100:7195-7200

Miller, et al., Mol. Cell. Biol., 1990, 10:4239

Minks et al., J. Biol. Chem., 1979, 254:10180

EXAMINER

DATE CONSIDERED

\* Examiner: Initial if document considered whether or not the information is considered relevant to the invention (PTO 1449)

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /K.C./

Substitute for form 1449A/PTO and/or 1449B/PTO  
**INFORMATION DISCLOSURE  
 STATEMENT BY APPLICANT**  
 (Use as many sheets as necessary)

Complete if Known

<b>Application Number</b>	10/522,954
<b>Filing Date</b>	January 31, 2005
<b>First Named Inventor</b>	Beverly L. Davidson
<b>Group Art Unit</b>	1635
<b>Examiner Name</b>	Unknown

Sheet 11 of 14

**Attorney Docket No:** 17023.045US2

**OTHER DOCUMENTS – NON PATENT LITERATURE DOCUMENTS**

**Examiner Initials\*** Include last name of the first author (in CAPITAL letters), Title of the Source (book, magazine, journal, serial, symposium, catalog, etc.), Volume-Number, page(s) and (date).

Miyagishi et al., Nature Biotechnology, 2002, 19:497-499

Molling, J Mol Med., 1997, 75(4):242-246

Moulder et al., J. Neurosci., 1999, 19:705-715

Mullan et al., Nature Genetics, 1992, 1:345-347

Myers and Miller, CABIOS, 1988, 4:11

Nasir et al., Cell, 1995, 81:811-823

Needleman and Wunsch, JMB, 1970, 48:443

Nellemann et al., Mol Cell Neurosci, 2000;16(4):313-323.

Nykänen et al., Cell, 2001, 107:309-321

Oddo et al., Neuron, 2003, 39(3):409-421

Ogura and Wilkinson, Genes Cells, 2001, 6:575-597

Ohtsuka et al., JBC, 1985, 260:2605

Okabe et al., FEBS Lett, 1997, 407:313-319

Ooboshi et al., Arterioscler. Thromb. Vasc. Biol., 1997, 17:1786-1792

Ozelius et al., Genomics, 1999, 62:377-384

Ozelius et al., Nature Genetics, 1997, 17:40-48

Paddison et al., Genes and Development, 2002, 16:948-958

Paddison et al., PNAS, 2002, 99:1443-1448

Pardoll et al., Immunity, 1995, 3(2):165-169

Paul et al., Nature Biotechnology, 2002, 29:505-508

Paule et al., Nucleic Acids Research, 2000, 28:1283-1298

**EXAMINER**

**DATE CONSIDERED**

Substitute Information Disclosure Statement Form (PTO-1449)

\* Examiner Initial if document considered, whether or not the citation is in accordance with MPEP 2106. Please fill in through column 3 and consider the nature of the form with most communication to the inventor.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /K.C./

Substitute for form 1449A/PTO and/or 1449B/PTO  
**INFORMATION DISCLOSURE  
 STATEMENT BY APPLICANT**  
 (Use as many sheets as necessary)

Complete if Known

<b>Application Number</b>	10/522,954
<b>Filing Date</b>	January 31, 2005
<b>First Named Inventor</b>	Beverly L. Davidson
<b>Group Art Unit</b>	1635
<b>Examiner Name</b>	Unknown

Sheet 12 of 14

Attorney Docket No: 17023.045U2

**OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS**

**Examiner Initials\*** Include last name of the first author (in CAPITAL letters), Title of the Source (book, magazine, journal, serial, symposium, catalog, etc.), Volume-Number, page(s) and (date).

Paulson et al., Ann. Neurol., 1997, 41(4):453-462

Pearson and Lipman, PNAS, 1988, 85:2444

Pearson et al., Meth. Mol. Biol., 1994, 24:307

Pham et al., Cell, 2004, 117:83-94

Pittman et al., J. Neurosci., 1993, 13(9):3669-3680

Poorkaj et al., Ann. Neurol., 1998, 43:815-825

Quantin et al., PNAS, 1992, 89:2581

Reynolds et al., Nat. Biotechnol., 2004, 22:326-30

Rosenfeld et al., Science, 1991, 252:431

Rossolini et al., Mol. Cell. Probes, 1994, 8:91

Rubinson et al., Nature Genetics, 2003, 33:401-406

Scharfmann et al., PNAS, 1991, 88:4626

Schilling et al., Hum Mol Genet., 1999, 8(3):397-407

Schilling et al., Neurobiol Dis., 2001, 8:405-418

Schramke et al., Nature, 2005, 435:1275-1279

Schwarz et al., Cell, 2003, 115(2):199-208

Schwarz et al., Mol. Cell., 2002, 10(3):537-548

Sharp, Genes and Development, 1999, 13:139-141

Shi et al., RNA, 2000, 6:1069-1076

Shipley et al., J. Biol. Chem., 1993, 268:12193

Sisodia et al., Nat Rev., 2002, 3(4):281-290

EXAMINER

DATE CONSIDERED

\* Examiner: Initial if documents considered, otherwise not. (The official name of the document is "Information Disclosure Statement Form (PTO-1449)".)

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. //K.C./

Substitute for form 1449A/PTO and/or 1449B/PTO  
**INFORMATION DISCLOSURE  
 STATEMENT BY APPLICANT**  
 (Use as many sheets as necessary)

Complete if Known

Application Number	10/522,954
Filing Date	January 31, 2005
First Named Inventor	Beverly L. Davidson
Group Art Unit	1635
Examiner Name	Unknown

Sheet 13 of 14

Attorney Docket No: 17023.045US2

**OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Include last name of the first author (in CAPITAL letters), Title of the Source (book, magazine, journal, serial, symposium, catalog, etc.), Volume-Number, page(s) and (date).
	Sledz et al., <u>Nat Cell Biol.</u> , 2003, 5:834-839
	Smith et al., <u>Adv. Appl. Math.</u> , 1981, 2:482
	Song et al., <u>Nat. Med.</u> , 2003, 9:347-351
	Stein et al., <u>J. Virol.</u> , 1999, 73:34243429
	Stein et al., <u>RNA</u> , 2003, 9(2):187-192
	Sui et al., <u>PNAS</u> , 2002, 99:(8)5515-5520
	Svoboda et al., <u>Development</u> , 2000, 127:4147-4156
	Tabara et al., <u>Cell</u> , 1999, 99:123-132
	Tanemura et al., <u>J. Neurosci.</u> , 2002, 22(1):133-141
	Tang et al., <u>Genes Dev.</u> , 2003, 17(1):49-63
	Temin, "Retrovirus vectors for gene transfer", <u>Gene Transfer</u> , Kucherlapati R, Ed., pp 149-187, Plenum, 1986
	Tijsterman et al., <u>Cell</u> , 2004; 117(1):1-3.
	Timmons et al., <u>Nature</u> , 1998, 395:854
	Tritz et al., "Screening Promoters for Optimal Expression of Ribozymes", 1999, pages 115-123, in Intracellular Ribozyme Applications: Principles and Protocols, Horizon Scientific Press.
	Trotter et al., <u>Nature</u> , 1995, 378(6555):403-406
	Turner et al., <u>Mol. Biotech.</u> , 1995, 3:225
	Tuschl, <u>Nat. Biotechnol.</u> , 2002, 20:446-448
	Valerio et al., <u>Gene</u> , 1989, 84:419
	Verma et al., <u>Nature</u> , 1997, 389:239-242
	Viera et al., <u>Meth. Enzymol.</u> , 1987, 153:3

EXAMINER

DATE CONSIDERED

\* Examiner, list all documents considered, whether or not the document has correspondence with the PTO. Do not list documents that are not considered by the PTO.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. //K.C./

Complete if Known

<b>Application Number</b>	10/522,954
<b>Filing Date</b>	January 31, 2005
<b>First Named Inventor</b>	Beverly L. Davidson
<b>Group Art Unit</b>	1635
<b>Examiner Name</b>	Unknown

Sheet 14 of 14

Attorney Docket No: 17023.045US2

**OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS**

<b>Examiner Initials*</b>	<b>Include last name of the first author (in CAPITAL letters), Title of the Source (book, magazine, journal, serial, symposium, catalog, etc.), Volume-Number, page(s) and (date).</b>
	Wagner et al., <u>Nature</u> , 1998, 391:744-745
	Walker et al., <u>Neurology</u> , 2002, 58:120-124
	Waterhouse et al., <u>PNAS</u> , 1998, 95:13959-13964
	Wianny et al., <u>Nat. Cell Biol.</u> , 2000, 2:70-75
	Xia et al., <u>Nature Biotechnology</u> , 2002, 20:1006-1010
	Xia et al., <u>Nat. Biotechnol.</u> , 2001, 19:640-644
	Xia et al., <u>Nat Med</u> , 10(8):775-776 (2004).
	Yamamoto et al., <u>Cell</u> , 2000, 101(1):57-66
	Yang et al., <u>Molecular and Cellular Biology</u> , 2001, 21:7807-7816
	Yu et al., <u>PNAS</u> , 2002, 99(9):6047-6052
	Yu et al., <u>J Neurosci</u> , 2003, 23:2193-2202
	Zamore et al., <u>Cell</u> , 2000, 101:25-33
	Zeng et al., <u>PNAS</u> , 2003, 100(17):9779-9784
	Zeng et al., <u>RNA</u> , 2003, 9(1), 112-123
	Zoghbi and On, <u>Annu. Rev. Neurosci.</u> , 2000, 23:217-247

EXAMINER /Kimberly Chong/

DATE CONSIDERED 03/23/2010

\* Examiner: Initial 5 documents considered, whether or not the citation is in conformance with MPEP 609. Draw line through citation if not considered. Include copy of this form with next communication to Applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /K.C./